{"schema_version":"1.0","type":"article","title":"藥華藥 打開估值想像空間","url":"https://drugnews.com.tw/articles/2026-05-14-pharmaessentia-besremi-mpn-valuation.html","markdown_url":"https://drugnews.com.tw/articles/2026-05-14-pharmaessentia-besremi-mpn-valuation.md","lang":"zh-Hant","date":"2026-05-14","publish_at":"2026-05-14T10:30:00+08:00","updated_at":"2026-05-14","category":"商業分析系列","topic":"商業分析系列","tags":["Dcard","免費文章","ADC","FDA","藥華藥","BESREMi","生技投資"],"summary":"因為 BESREMi（ropeginterferon alfa-2b）在台灣正式獲衛福部核准用於原發性血小板過多症（Essential Thrombocythemia, ET）成人病人，適用於接受 Hydroxyurea 治療後產生抗藥性或無法耐受的患者。","key_points":[],"facts":[],"sections":["01｜為什麼 BESREMi 不是普通幹擾素？","02｜PV：BESREMi 第一個打穿的全球市場","03｜今天 ET 核准，為什麼是另一個關鍵節點？","04｜ET 的國際線：美國 FDA 與 NCCN 已經提前給出訊號","05｜PV 市場不大，但商業價值不能用「病人數」粗暴低估"],"references":[{"title":"[1]:","source":"","date":"","url":""},{"title":"藥華藥 (6446) 本公司新藥BESREMi（Ropeginterferon alfa-2b）獲 衛福部使用於原發性血小板過多症（ET）核准函","source":"GeneOnline News","date":"","url":""},{"title":"序號：3 發言日期：115/05/12 發言時間：23:06:44 發言人：林國鐘 發言人職稱：執行長 發言人","source":"","date":"","url":""},{"title":"geneonline.news","source":"","date":"","url":""},{"title":"\"藥華藥 (6446) 本公司新藥BESREMi（Ropeginterferon alfa-2b）獲 衛福部使用於原發性血小板過多症（ET）核准函","source":"GeneOnline News\"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"www.sciencedirect.com","source":"","date":"","url":""},{"title":"https://www.sciencedirect.com/science/article/abs/pii/S2352302619302364","source":"","date":"","url":"https://www.sciencedirect.com/science/article/abs/pii/S2352302619302364"},{"title":"www.sciencedirect.com","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"Besremi","source":"European Medicines Agency (EMA","date":"","url":""},{"title":"https://www.ema.europa.eu/en/medicines/human/EPAR/besremi","source":"","date":"","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/besremi"},{"title":"www.ema.europa.eu","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"藥華藥(6446)新藥美國市場重大突破 獲美國NCCN治療指南  升格為 PV病患首選藥物 - 生技投資第一站-Genet 觀點","source":"","date":"","url":""},{"title":"藥華藥（台灣櫃買中心股票代碼：6446）今（21）日宣布，美國國家綜合癌症資訊網NCCN（National Comprehensive Cancer Network）在最新的治療指南中，將BESREMi®（Ropeginterferon alfa-2b-njft，簡稱Ropeg，即P1101）在治療成人真性紅血球增多症（Polycythemia vera, PV），從「其他推薦」（other recommendation）升格為「首選藥物2A」（preferred regimen），預料將對美國銷售、以及","source":"","date":"","url":""},{"title":"www.genetinfo.com","source":"","date":"","url":""},{"title":"\"藥華藥(6446)新藥美國市場重大突破 獲美國NCCN治療指南 升格為 PV病患首選藥物 - 生技投資第一站-Genet 觀點\"","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"Linkedin","source":"","date":"","url":""},{"title":"EXCEED-ET Study Results Demonstrate Significant Efficacy, with Consistent Treatment Response Across the Overall Essential Thrombocythemia Population Results Extend Previously Reported Positive Phase 3 SURPASS-ET Study Data, Demonstrating Superior Efficacy","source":"","date":"","url":""},{"title":"us.pharmaessentia.com","source":"","date":"","url":""},{"title":"\"PharmaEssentia Announces Positive Topline Phase 2b Data from EXCEED-ET Study Evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia - PharmaEssentia\"","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：藥華藥 打開估值想像空間","url":"https://drugnews.com.tw/assets/articles/pharmaessentia-besremi-mpn-valuation/dcard-01.webp"},{"alt":"Dcard 原圖：藥華藥 打開估值想像空間","url":"https://drugnews.com.tw/assets/articles/pharmaessentia-besremi-mpn-valuation/dcard-02.png"},{"alt":"Dcard 原圖：藥華藥 打開估值想像空間","url":"https://drugnews.com.tw/assets/articles/pharmaessentia-besremi-mpn-valuation/dcard-03.png"},{"alt":"Dcard 原圖：藥華藥 打開估值想像空間","url":"https://drugnews.com.tw/assets/articles/pharmaessentia-besremi-mpn-valuation/dcard-04.jpg"}],"cover_image":"https://drugnews.com.tw/assets/articles/pharmaessentia-besremi-mpn-valuation/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-05-14）。藥華藥 打開估值想像空間。https://drugnews.com.tw/articles/2026-05-14-pharmaessentia-besremi-mpn-valuation.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-05-14-pharmaessentia-besremi-mpn-valuation-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}